270 related articles for article (PubMed ID: 25672887)
1. Role of Bruton's tyrosine kinase inhibitors in HIV-1-infected cells.
Guendel I; Iordanskiy S; Sampey GC; Van Duyne R; Calvert V; Petricoin E; Saifuddin M; Kehn-Hall K; Kashanchi F
J Neurovirol; 2015 Jun; 21(3):257-75. PubMed ID: 25672887
[TBL] [Abstract][Full Text] [Related]
2. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide].
Mahajan S; Ghosh S; Sudbeck EA; Zheng Y; Downs S; Hupke M; Uckun FM
J Biol Chem; 1999 Apr; 274(14):9587-99. PubMed ID: 10092645
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism.
Rotin LE; Gronda M; MacLean N; Hurren R; Wang X; Lin FH; Wrana J; Datti A; Barber DL; Minden MD; Slassi M; Schimmer AD
Oncotarget; 2016 Jan; 7(3):2765-79. PubMed ID: 26624983
[TBL] [Abstract][Full Text] [Related]
4. Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.
Bam R; Ling W; Khan S; Pennisi A; Venkateshaiah SU; Li X; van Rhee F; Usmani S; Barlogie B; Shaughnessy J; Epstein J; Yaccoby S
Am J Hematol; 2013 Jun; 88(6):463-71. PubMed ID: 23456977
[TBL] [Abstract][Full Text] [Related]
5. Clinical potential of targeting Bruton's tyrosine kinase.
Uckun FM
Int Rev Immunol; 2008; 27(1-2):43-69. PubMed ID: 18300055
[TBL] [Abstract][Full Text] [Related]
6. Bruton's tyrosine kinase as a new therapeutic target.
Uckun FM; Tibbles HE; Vassilev AO
Anticancer Agents Med Chem; 2007 Nov; 7(6):624-32. PubMed ID: 18045057
[TBL] [Abstract][Full Text] [Related]
7. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
[TBL] [Abstract][Full Text] [Related]
8. The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity.
van den Akker E; van Dijk TB; Schmidt U; Felida L; Beug H; Löwenberg B; von Lindern M
Biol Chem; 2004 May; 385(5):409-13. PubMed ID: 15196000
[TBL] [Abstract][Full Text] [Related]
9. Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA).
Heinonen JE; Smith CI; Nore BF
FEBS Lett; 2002 Sep; 527(1-3):274-8. PubMed ID: 12220673
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Bruton's Tyrosine Kinase Modulates Microglial Phagocytosis: Therapeutic Implications for Alzheimer's Disease.
Keaney J; Gasser J; Gillet G; Scholz D; Kadiu I
J Neuroimmune Pharmacol; 2019 Sep; 14(3):448-461. PubMed ID: 30758770
[TBL] [Abstract][Full Text] [Related]
11. Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia.
Rushworth SA; Murray MY; Zaitseva L; Bowles KM; MacEwan DJ
Blood; 2014 Feb; 123(8):1229-38. PubMed ID: 24307721
[TBL] [Abstract][Full Text] [Related]
12. Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.
Stiff A; Trikha P; Wesolowski R; Kendra K; Hsu V; Uppati S; McMichael E; Duggan M; Campbell A; Keller K; Landi I; Zhong Y; Dubovsky J; Howard JH; Yu L; Harrington B; Old M; Reiff S; Mace T; Tridandapani S; Muthusamy N; Caligiuri MA; Byrd JC; Carson WE
Cancer Res; 2016 Apr; 76(8):2125-36. PubMed ID: 26880800
[TBL] [Abstract][Full Text] [Related]
13. Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells.
Nadeem A; Ahmad SF; Al-Harbi NO; El-Sherbeeny AM; Alasmari AF; Alanazi WA; Alasmari F; Ibrahim KE; Al-Harbi MM; Bakheet SA; Attia SM
Int Immunopharmacol; 2020 Mar; 80():106215. PubMed ID: 31982823
[TBL] [Abstract][Full Text] [Related]
14. Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib.
Liu L; Shi B; Wang X; Xiang H
Future Med Chem; 2018 Feb; 10(3):343-356. PubMed ID: 29347836
[TBL] [Abstract][Full Text] [Related]
15. Bruton's tyrosine kinase drives neuroinflammation and anxiogenic behavior in mouse models of stress.
Ghosh S; Mohammed Z; Singh I
J Neuroinflammation; 2021 Dec; 18(1):289. PubMed ID: 34895246
[TBL] [Abstract][Full Text] [Related]
16. Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer.
Kokabee L; Wang X; Sevinsky CJ; Wang WL; Cheu L; Chittur SV; Karimipoor M; Tenniswood M; Conklin DS
Cancer Biol Ther; 2015; 16(11):1604-15. PubMed ID: 26383180
[TBL] [Abstract][Full Text] [Related]
17. Bruton's tyrosine kinase is required for TLR-dependent heme oxygenase-1 gene activation via Nrf2 in macrophages.
Vijayan V; Baumgart-Vogt E; Naidu S; Qian G; Immenschuh S
J Immunol; 2011 Jul; 187(2):817-27. PubMed ID: 21677132
[TBL] [Abstract][Full Text] [Related]
18. In vivo pharmacokinetic features, toxicity profile, and chemosensitizing activity of alpha-cyano-beta-hydroxy-beta- methyl-N-(2,5-dibromophenyl)propenamide (LFM-A13), a novel antileukemic agent targeting Bruton's tyrosine kinase.
Uckun FM; Zheng Y; Cetkovic-Cvrlje M; Vassilev A; Lisowski E; Waurzyniak B; Chen H; Carpenter R; Chen CL
Clin Cancer Res; 2002 May; 8(5):1224-33. PubMed ID: 12006542
[TBL] [Abstract][Full Text] [Related]
19. Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice.
O'Riordan CE; Purvis GSD; Collotta D; Chiazza F; Wissuwa B; Al Zoubi S; Stiehler L; Martin L; Coldewey SM; Collino M; Thiemermann C
Front Immunol; 2019; 10():2129. PubMed ID: 31552054
[TBL] [Abstract][Full Text] [Related]
20. Single cell imaging of Bruton's tyrosine kinase using an irreversible inhibitor.
Turetsky A; Kim E; Kohler RH; Miller MA; Weissleder R
Sci Rep; 2014 Apr; 4():4782. PubMed ID: 24759210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
